Loading...

Mettler-Toledo International Inc.

0K10.LLSE
Healthcare
Medical - Pharmaceuticals
£1279.69
£-40.36(-3.06%)

Mettler-Toledo International Inc. (0K10.L) Financial Performance & Income Statement Overview

Review Mettler-Toledo International Inc. (0K10.L) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.

Revenue Growth
2.22%
2.22%
Operating Income Growth
-2.16%
2.16%
Net Income Growth
9.43%
9.43%
Operating Cash Flow Growth
0.26%
0.26%
Operating Margin
29.15%
29.15%
Gross Margin
58.17%
58.17%
Net Profit Margin
22.29%
22.29%
ROE
-582.49%
582.49%
ROIC
54.49%
54.49%

Mettler-Toledo International Inc. (0K10.L) Income Statement & Financial Overview

Access detailed annual and quarterly income data for Mettler-Toledo International Inc. 0K10.L financial performance.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$883.74M$1.05B$954.53M$946.75M
Cost of Revenue$357.87M$405.81M$382.07M$399.26M
Gross Profit$525.88M$639.32M$572.47M$547.49M
Gross Profit Ratio$0.60$0.61$0.60$0.58
R&D Expenses$46.35M$50.05M$47.12M$45.77M
SG&A Expenses$242.80M$237.34M$228.78M$235.80M
Operating Expenses$289.14M$287.39M$275.89M$281.57M
Total Costs & Expenses$647.01M$656.80M$657.96M$680.83M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$16.65M$17.85M$18.60M$18.95M
Depreciation & Amortization$18.14M$30.86M$31.08M$30.53M
EBITDA$236.73M$363.26M$308.63M$295.76M
EBITDA Ratio$0.27$0.35$0.32$0.31
Operating Income$236.73M$333.70M$332.98M$265.92M
Operating Income Ratio$0.27$0.32$0.35$0.28
Other Income/Expenses (Net)-$34.79M-$19.15M-$74.03M-$22.75M
Income Before Tax$201.94M$314.55M$258.95M$243.18M
Income Before Tax Ratio$0.23$0.30$0.27$0.26
Income Tax Expense$38.35M$62.25M$47.44M$21.36M
Net Income$163.59M$252.30M$211.52M$221.81M
Net Income Ratio$0.19$0.24$0.22$0.23
EPS$7.84$12.00$9.94$10.42
Diluted EPS$7.84$11.96$9.94$10.37
Weighted Avg Shares Outstanding$20.87M$21.02M$21.29M$21.28M
Weighted Avg Shares Outstanding (Diluted)$20.87M$21.10M$21.29M$21.39M

Over the past four quarters, Mettler-Toledo International Inc. demonstrated steady revenue growth, increasing from $946.75M in Q2 2024 to $883.74M in Q1 2025. Operating income reached $236.73M in Q1 2025, maintaining a consistent 27% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $236.73M, reflecting operational efficiency. Net income dropped to $163.59M, with EPS at $7.84. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;